Background/Aim: A randomized controlled trial was conducted involving 67 stable adult haemodialysis patients with hyperphosphataemia. The objective was to determine the effect of monthly dietetic consultations on patients’ serum phosphate concentrations and calcium × phosphate product. Methods: The intervention group received monthly dietetic consultations for 6 months using advanced counselling skills aimed at limiting phosphate intake in the diet and improving compliance with phosphate binders, whereas standard care with dietetic consultations every 6 months was provided to the control group. Results: Serum phosphate concentrations decreased in the intervention group from 2.05 ± 0.48 to 1.80 ± 0.48 mmol/l by month 3 (p < 0.05). However, this subsequently increased and by month 6 there was no significant difference from baseline. After controlling for confounding variables, the difference between the groups was approaching significance at month 3, but there was no difference by month 6, or following conclusion of the study. The calcium × phosphate product similarly decreased in both groups, achieving K/DOQI standards, but was not sustained either during the remainder of the study but decreased further by the 12-month follow-up and, although it was not significantly different, it did improve significantly from baseline in both the intervention and control groups. Conclusion: Increased frequency of dietetic consultations can result in improved phosphate control in the short term, and therefore more innovative strategies appear necessary to sustain longer-term control.

Keywords:
Compliance, phosphate control, Dietitian, Hyperphosphataemia, Haemodialysis, dietetic time, Nutrition, Phosphate
1.
Block GA, Hulbert-Shearon TE, Levin NW, et al: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607–617.
2.
Goodman WG, Goldin J, Kuizon BD, et al: Coronary artery calcification in young adults with end-stage-renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478–1483.
3.
Ganesh SK, Stack AG, Levin NW, et al: Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131–2138.
4.
Raggi P, Boulay A, Chasan-Taber S, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695–701.
5.
Slatopolsky E, Dusso A, Brown AJ: The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am J Med Sci 1999;317:370–376.
6.
Yi H, Fukagawa M, Kurokawa K: Mild dietary phosphorus restriction directly prevents enhanced parathyroid hormone secretion and synthesis and proliferation of parathyroid cells in chronic renal failure (abstract). J Am Soc Nephrol 1992;3:703.
7.
Pei Y, Hercz G, Greenwood C, et al: Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res 1995;10:149–156.
8.
Llach F, Yudd M: The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 1998;13(suppl 3):57–61.
9.
Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226–1237.
10.
Haynes RB, Yao X, Degani A, et al: Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005;2:CD000011.
11.
Durose CL, Holdsworth M, Watson V, et al: Knowledge of dietary restrictions and the medical consequences of noncompliance by patients on hemodialysis are not predictive of dietary compliance. J Am Diet Assoc 2004;104:35–41.
12.
Ashurst Ide B, Dobbie H: A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients. J Ren Nutr 2003;13:267–274.
13.
Ford JC, Pope JF, Hunt AE, et al: The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia. J Ren Nutr 2004;14:36–44.
14.
Gillis BP, Caggiula AW, Chiavacci AT, et al: Nutrition intervention program of the Modification of Diet in Renal Disease Study: a self-management approach. J Am Diet Assoc 1995;95:1288–1294.
15.
Locatelli F, Cannata-Andía JB, Drüeke TB, et al: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002;17:723–731.
16.
Renal Association: Treatment of Adults and Children with Renal Failure: Standards and Audit Measures, ed 3. London, Royal College of Physicians of London and the Renal Association, 2002.
17.
National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3):S1–S201.
18.
Rufino M, García S, Jiménez A, et al: Heart valve calcification and calcium × phosphorus product in hemodialysis patients: analysis of optimum values for its prevention. Kidney Int Suppl 2003;85:115–118.
19.
Prochaska JO, DiClemente CC: Transtheoretical therapy: toward a more integrative model of change. Psychother Theory Res Pract 1982;19:276–288.
20.
Cukor D, Peterson RA, Cohen SD, et al: Depression in end-stage renal disease hemodialysis patients. Nat Clin Pract Nephrol 2006;2:678–687.
21.
Kimmel PL, Peterson RA: Depression in end-stage renal disease patients treated with hemodialysis: tools, correlates, outcomes, and needs. Semin Dial 2005;18:91–97.
22.
Deakin T, McShane CE, Cade JE, et al: Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;2:CD003417.
23.
Steed L, Lankester J, Barnard M, et al: Evaluation of the UCL diabetes self-management programme (UCL-DSMP): a randomized controlled trial. J Health Psychol 2005;10:261–276.
24.
Norris SL, Engelgau MM, Narayan KM: Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001;24:561–587.
25.
Shaw-Stuart NJ, Stuart A: The effect of an educational patient compliance program on serum phosphate levels in patients receiving hemodialysis. J Ren Nutr 2000;10:80–84.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.